Source:http://linkedlifedata.com/resource/pubmed/id/12021115
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
2002-5-21
|
| pubmed:abstractText |
The tyrosine phosphatase-like protein IA-2 is an important islet autoantigen in type 1 diabetes. Although the radioligand binding assay with in vitro synthesized (35)S-labeled antigen has been used extensively for measuring autoantibodies to IA-2, disadvantages of both assays with respect to synthesis and handling of the radioactive antigen limit their use in routine laboratories. Therefore, we attempted to develop a nonradioactive ELISA for the simple detection of IA-2 autoantibodies. The biotinylated cytoplasmic domain of IA-2 expressed in Escherichia coli was used as an antigen. We evaluated two kinds of ELISA: ELISA with biotin-IA-2 directly captured on streptavidine-coated plates (solid phase) and ELISA with antigen-antibody preincubation in solution in which serum samples were reacted first with biotin-IA-2 and the mixture was transferred to streptavidine-coated plates (liquid phase). We compared their disease sensitivity and specificity with a conventional radioligand binding assay in 52 patients with recent-onset type 1 diabetes and 138 normal individuals. The radioligand binding assay had 61.5% sensitivity and 99.3% specificity. The liquid-phase ELISA showed relatively higher sensitivity (55.8%) and specificity (99.3%) than the solid-phase ELISA (sensitivity 53.8% and specificity 97.1%). Furthermore, the mean SD score in IA-2 autoantibody-positive serum samples measured by liquid-phase ELISA was significantly higher than the SD score obtained by solid-phase ELISA (P < 0.0001). We concluded that this liquid-phase ELISA is suitable for detecting IA-2 autoantibodies in patients with type 1 diabetes with a similar sensitivity and specificity to those of conventional radioligand binding assay.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
0077-8923
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
958
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
241-6
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:12021115-Adolescent,
pubmed-meshheading:12021115-Adult,
pubmed-meshheading:12021115-Age of Onset,
pubmed-meshheading:12021115-Autoantibodies,
pubmed-meshheading:12021115-Child,
pubmed-meshheading:12021115-Diabetes Mellitus, Type 1,
pubmed-meshheading:12021115-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:12021115-Female,
pubmed-meshheading:12021115-Humans,
pubmed-meshheading:12021115-Male,
pubmed-meshheading:12021115-Middle Aged,
pubmed-meshheading:12021115-Radioligand Assay,
pubmed-meshheading:12021115-Sensitivity and Specificity
|
| pubmed:year |
2002
|
| pubmed:articleTitle |
Autoantibodies to IA-2 in type 1 diabetes: measurements with a new enzyme-linked immunosorbent assay.
|
| pubmed:affiliation |
The First Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki 852-8501, Japan. f1196@cc.nagasaki-u.ac.jp
|
| pubmed:publicationType |
Journal Article
|